Navigation Links
RunWay Femoral Left

ProductsRunWay Femoral Left
Company Boston Scientific Corporation
Item RunWay Femoral Left
Features 
  • Primary and secondary curve firmness provide excellent back-up support.
  • Innovative polymer designed to enhance curve retention.
  • Excellent shaft firmness designed to enhance pushability through tortuous anatomy.
  • Innovative braid design designed to resist kinking.
  • Exceptional torque response designed to enhance maneuverability.
  • Soft tip for confident engagement.
  • Radiopaque tip for clear visualization and accurate positioning.
Description For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters.
Info Boston Scientific Corporation
Customer Service: (888) 272-1001
Web site: http://www.bostonscientific.com

Related medicine products :

1. RunWay™ Femoral Left Short Tip
2. RunWay™ Femoral Left
3. RunWay™ Femoral Curve Left
4. RunWay Femoral Curve Left
5. VG1 ALIF (Anterior) Femoral Trapezoid
6. VG1 ALIF (Anterior Lateral) Femoral Trapezoid
7. Vertigraft Femoral Shaft
8. Genus Unicondylar Knee System - Femoral Components
9. Vanguard M Unicondylar Knee System - Femoral Components
10. Advance Uni-Comparental Knee Components - Uni Femoral Components.
11. BioPro Uni-compartmental Knee System - Femoral Component
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base.
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base.
Medicine Products:
(Date:12/2/2008)...ewswire/ -- At a symposium today hosted by Johns,... Science researchers presented,the latest researc...lating the,science into technology to improve liv..., presented evidence that cognitive intervention d...sticity, the brain,s ability to,reorganize itself...
(Date:12/2/2008)...RNewswire-USNewswire/ -- Are you unhappy with your...ptions are available? , , The Pennsylvania ...ny cosmetic options exist to improve your smile. Y...al history to determine a suitable option to help ... cosmetic dental options. , , , , ...
(Date:12/2/2008)...uries accounted for 3.5 percent of high school ath...e first study to examine rare injuries and conditi...clude eye injuries, dental injuries, neck and cerv...ich may result in high morbidity, costly surgeries... Football was associated with the highest rate of ...
(Date:12/2/2008)...wire-USNewswire/ -- In an open letter to President... and Services for the Aging (AAHSA) President and ...Obama administration can make both short-term gain...ca cares for its most vulnerable people. , ,...on,s Work Force: Create Jobs in Aging Services; ,...
Breaking Medicine News(10 mins):Health News:Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions 2Health News:Cosmetic Dentistry: A Beautiful Smile Is Not Far Away 2
... reason to quit smoking, by finding that regular s...ssion in comparison to those who never smoke. The ...have an elevated risk of depressive symptoms in sh...lines to the level of never smokers in the long ru...
...ian diet reduces risk of colon cancer . Another r...uces food intake by about 20 percent. The researc...your diet regimen or ordering an appetizer for din...lp in managing a healthy lifestyle. Researchers f...
...ario has emerged a heartening development.The Worl...mycin IM injection manufactured by the US based In...m, for inclusion in its Model List for Essential M... is a cost-effective treatment for visceral leishm...
...ene sequencing is able to help confirm 24 lysosoma...nts the tools for much more accurate and rapid di... more than 40 inherited and potentially life-threa...on in cellular compartments called lysosomes. This...
Other Medicine News:Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 3Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 4Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 3Health News:New DNA Tests Advances Treatment of Lysosomal Storage Diseases 2
(Date:12/1/2008)...-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq:... of the world,s leading medical journals, results ...r, experimental compound tasimelteon (VEC-162). T..."Melatonin agonist tasimelteon (VEC-162) for trans...ed controlled multicentre trials." Results are rep...
(Date:12/1/2008)...-- Roche announced today that a,comparative study...in and,discomfort associated with blood glucose t...systems and lancing devices were deemed least pain... ACCU-CHEK Aviva and ACCU-CHEK Compact,Plus blood...iclix, ACCU-CHEK,Softclix and ACCU-CHEK Softclix ...
(Date:12/1/2008)... policy , , ROCHESTER, Minn., Dec. 1 /PRNe... finds the use of the drug therapy etanercept inef...inflammation of the liver caused by excessive cons...ublished in the December issue of Gastroenterolog...VIDEO ALERT: Additional audio and video resources,...
(Date:12/1/2008)...uesday, December 9 at 11:00 am ET to Discuss Phase...RANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ ..., a biopharmaceutical company focused on the devel...peutics, today announced new data from its studies... be presented during the 50th American Society of ...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Balloon Valve May Be Alternative to Open Heart Surgery 5437 1Balloon Valve May Be Alternative to Open Heart Surgery 5437 2Balloon Valve May Be Alternative to Open Heart Surgery 5437 3No increase in cardiovascular risk for living kidney donors 5433 1No increase in cardiovascular risk for living kidney donors 5433 2Healthcare Workers Community Activists Call for Fair Election Agreement at St Joseph Health System 5429 1Healthcare Workers Community Activists Call for Fair Election Agreement at St Joseph Health System 5429 2Emergency Care for Heart Attacks Pneumonia Fails to Meet Goals 5425 1Emergency Care for Heart Attacks Pneumonia Fails to Meet Goals 5425 2
...pen-Label Study Presented at Federation of,Clinica...ARLSBAD, Calif., June 11, 2007 /PRNewswire-FirstCa...d: OCHT) announced today,positive new data from it...TM), an investigational T Cell Receptor (TCR) pept...ng multiple sclerosis,(MS). The new data, presente...
... Phase 1 Clinical Trial of SNS-595 in Acute,Leukem...H SAN FRANCISCO, Calif., June 11, 2007,/PRNewswire...nted,positive data from clinical studies of two of...-595 and SNS-032, at the 12th,Congress of the Euro...ia. , Interim Results from Sunesis, Phase 1 Study ...
Other Medicine Technology:Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 2Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 3Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 4Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 6